Trial Profile
Clinical predictors of Bevacizumab-associated intestinal perforation in patients with non-small cell lung cancer: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 20 Mar 2018 New trial record
- 14 Mar 2018 Results published in the Investigational New Drugs